A Multi-Center Phase I/Ib Study Evaluating the Efficacy and Safety of Ublituximab, a Third- Generation Anti-CD20 Monoclonal Antibody, in Combination with TGR-1202, a Novel PI3k Delta Inhibitor; and Ibrutinib in Patients with B-cell Malignancies

SUMMARY

N/A

COH Protocol Number : 14138

ClinicalTrials.gov Number : NCT02006485

Principal Investigator : Siddiqi, Tanya M.D.

Sponsor : TG Therapeutics, Inc.

BRIEF ELIGIBILITY CRITERIA :

Eligible Ages : >=18

Gender : Either

Minimum Performance Status : ECOG/SWOG:2

Treatment Intent : Non-Adjuvant treatment

Prior Chemotherapy :

Brain Metastases :

Measurable Disease :